TOP - September 2022 Vol 15, No 5

TOP Sept 2022 cover

Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research annual meeting.
This section provides a brief overview of new indications for cancer drugs approved by the FDA between June 22, 2022, and August 11, 2022.
Page 2 of 2
Results 11 - 12 of 12